Dong‐Wan Kim

28.0k total citations · 6 hit papers
130 papers, 10.4k citations indexed

About

Dong‐Wan Kim is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Dong‐Wan Kim has authored 130 papers receiving a total of 10.4k indexed citations (citations by other indexed papers that have themselves been cited), including 98 papers in Oncology, 92 papers in Pulmonary and Respiratory Medicine and 19 papers in Molecular Biology. Recurrent topics in Dong‐Wan Kim's work include Lung Cancer Treatments and Mutations (82 papers), Lung Cancer Research Studies (47 papers) and Colorectal Cancer Treatments and Studies (31 papers). Dong‐Wan Kim is often cited by papers focused on Lung Cancer Treatments and Mutations (82 papers), Lung Cancer Research Studies (47 papers) and Colorectal Cancer Treatments and Studies (31 papers). Dong‐Wan Kim collaborates with scholars based in South Korea, United States and Taiwan. Dong‐Wan Kim's co-authors include Enriqueta Felip, Tarek Mekhail, Tony Mok, Tae Min Kim, Yi‐Long Wu, Benjamin Solomon, Keith D. Wilner, Fiona Blackhall, James Chih‐Hsin Yang and Kazuhiko Nakagawa and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Applied Physics Letters.

In The Last Decade

Dong‐Wan Kim

126 papers receiving 10.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

2014 2.3k citations Benjamin Solomon, Tony Mok et al. New England Journal of Medicine profile →
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

2015 1.6k citations James Chih‐Hsin Yang, Dong‐Wan Kim et al. New England Journal of Medicine profile →
Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study

2015 430 citations Sai‐Hong Ignatius Ou, Jin Seok Ahn et al. Journal of Clinical Oncology profile →
Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study

2017 363 citations Dong‐Wan Kim et al. Journal of Clinical Oncology profile →
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer

2018 285 citations Benjamin Solomon, Dong‐Wan Kim et al. Journal of Clinical Oncology profile →
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

2021 201 citations Dong‐Wan Kim, Byoung Chul Cho et al. Journal of Thoracic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dong‐Wan Kim South Korea	45	7.5k	6.9k	2.5k	1.8k	847	130	10.4k
Paul Baas Netherlands	58	11.6k 1.5×	8.5k 1.2×	1.8k 0.7×	1.4k 0.8×	541 0.6×	309	17.0k
Suzanne George United States	55	6.8k 0.9×	3.7k 0.5×	1.8k 0.7×	978 0.6×	1.2k 1.4×	257	11.7k
G. Thomas Budd United States	37	2.7k 0.4×	6.8k 1.0×	2.3k 0.9×	4.1k 2.3×	630 0.7×	174	9.9k
George R. Blumenschein United States	60	5.1k 0.7×	7.0k 1.0×	2.7k 1.1×	2.4k 1.4×	1.4k 1.6×	328	12.0k
Shahneen Sandhu Australia	46	5.9k 0.8×	6.0k 0.9×	3.2k 1.3×	2.1k 1.2×	503 0.6×	289	11.0k
Scott Gettinger United States	58	6.8k 0.9×	10.3k 1.5×	2.8k 1.1×	1.7k 1.0×	651 0.8×	258	13.2k
Beow Y. Yeap United States	68	10.3k 1.4×	7.1k 1.0×	3.1k 1.2×	2.2k 1.2×	1.1k 1.3×	206	14.4k
Joyce O’Shaughnessy United States	40	2.8k 0.4×	7.0k 1.0×	2.1k 0.9×	3.1k 1.7×	433 0.5×	240	9.6k
Joohyuk Sohn South Korea	44	5.6k 0.7×	7.9k 1.2×	1.8k 0.7×	3.3k 1.8×	609 0.7×	303	10.9k
Sanjay Popat United Kingdom	42	8.3k 1.1×	8.1k 1.2×	2.8k 1.1×	2.6k 1.5×	2.1k 2.4×	372	13.5k

Countries citing papers authored by Dong‐Wan Kim

Since Specialization

Citations

This map shows the geographic impact of Dong‐Wan Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dong‐Wan Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dong‐Wan Kim more than expected).

Fields of papers citing papers by Dong‐Wan Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dong‐Wan Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dong‐Wan Kim. The network helps show where Dong‐Wan Kim may publish in the future.

Co-authorship network of co-authors of Dong‐Wan Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Dong‐Wan Kim. A scholar is included among the top collaborators of Dong‐Wan Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dong‐Wan Kim. Dong‐Wan Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kim, Soo-Min, Jaemoon Koh, Tae Min Kim, et al.. (2025). Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer. iScience. 28(2). 111736–111736. 3 indexed citations

Cho, Byoung Chul, Ji‐Youn Han, Ki Hyeong Lee, et al.. (2024). Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201. Lung Cancer. 190. 107509–107509. 4 indexed citations

Solomon, Benjamin, Todd M. Bauer, Tony Mok, et al.. (2023). Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer. Future Oncology. 19(14). 961–973.

Huber, Rudolf M., Karin Holmskov Hansen, Luis Paz-Ares Rodríguez, et al.. (2019). Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. Journal of Thoracic Oncology. 15(3). 404–415. 101 indexed citations

Yang, James Chih‐Hsin, Frances A. Shepherd, Dong‐Wan Kim, et al.. (2019). Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report. Journal of Thoracic Oncology. 14(5). 933–939. 164 indexed citations

Remón, Jordi, Myung‐Ju Ahn, Nicolas Girard, et al.. (2019). Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018. Journal of Thoracic Oncology. 14(7). 1134–1155. 60 indexed citations

Schüler, Martin, Eng-Huat Tan, Kenneth J. O’Byrne, et al.. (2019). First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. Journal of Cancer Research and Clinical Oncology. 145(6). 1569–1579. 31 indexed citations

Gadgeel, Shirish M., Alice T. Shaw, Fabrice Barlési, et al.. (2019). <p>Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (<em>ALK</em>)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies</p>. PubMed. Volume 10. 125–130. 7 indexed citations

Keam, Bhumsuk, Chan-Young Ock, Miso Kim, et al.. (2019). A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer. Lung Cancer. 136. 122–128. 44 indexed citations

10.

Solomon, Benjamin, Dong‐Wan Kim, Yi‐Long Wu, et al.. (2018). Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 36(22). 2251–2258. 285 indexed citations breakdown →

11.

Lim, Yu Jin, Ji Hyun Chang, Hak-Jae Kim, et al.. (2016). Superior Treatment Response and In-field Tumor Control in Epidermal Growth Factor Receptor-mutant Genotype of Stage III Nonsquamous Non–Small cell Lung Cancer Undergoing Definitive Concurrent Chemoradiotherapy. Clinical Lung Cancer. 18(3). e169–e178. 18 indexed citations

12.

Kim, Ryul, Chan-Young Ock, Bhumsuk Keam, et al.. (2016). Predictive and prognostic value of PET/CT imaging post-chemoradiotherapy and clinical decision-making consequences in locally advanced head & neck squamous cell carcinoma: a retrospective study. BMC Cancer. 16(1). 116–116. 24 indexed citations

13.

Kim, Tae Min, Dong‐Wan Kim, Soyeon Kim, et al.. (2015). Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1 -Rearranged Non–Small Cell Lung Cancer. Clinical Cancer Research. 21(10). 2379–2387. 99 indexed citations

14.

Ou, Sai‐Hong Ignatius, Jin Seok Ahn, Luigi De Petris, et al.. (2015). Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study. Journal of Clinical Oncology. 34(7). 661–668. 430 indexed citations breakdown →

15.

Koh, Jaemoon, Heounjeong Go, Bhumsuk Keam, et al.. (2015). Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status. Modern Pathology. 28(9). 1154–1166. 142 indexed citations

16.

Solomon, Benjamin, Tony Mok, Dong‐Wan Kim, et al.. (2014). First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. New England Journal of Medicine. 371(23). 2167–2177. 2327 indexed citations breakdown →

17.

Go, Se‐Il, Bhumsuk Keam, Tae Min Kim, et al.. (2013). Clinical Significance of Downstaging in Patients With Limited-Disease Small-Cell Lung Cancer. Clinical Lung Cancer. 15(2). e1–e6. 2 indexed citations

18.

Kim, Tae Min, Ki Hwan Kim, Min Joung Lee, et al.. (2010). First‐line therapy with doxycycline in ocular adnexal mucosa‐associated lymphoid tissue lymphoma: A retrospective analysis of clinical predictors. Cancer Science. 101(5). 1199–1203. 38 indexed citations

19.

Kim, Dong‐Wan, Se‐Hoon Lee, Jong Seok Lee, et al.. (2010). A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations. Lung Cancer. 71(1). 65–69. 33 indexed citations

20.

Oh, Dong Yoon, et al.. (2006). Antibiotic use during the last days of life in cancer patients. European Journal of Cancer Care. 15(1). 74–79. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact